GoodRx has expanded its self‑pay drug marketplace by adding the higher‑dose Wegovy HD, a 7.2 mg semaglutide injection, to its platform. The new product is priced at $399 per month, with a two‑month supply available for $798 and a three‑month supply for $1,197, giving consumers clear, scalable cost options.
The launch aligns with GoodRx’s strategy to broaden its GLP‑1 portfolio and support patients who cannot rely on insurance coverage. It also dovetails with the company’s growing Pharma Direct and subscription‑service initiatives, which grew 41% year‑over‑year in 2025 and represent a key shift toward direct manufacturer partnerships.
GoodRx’s Q4 2025 results provide context for the launch. The company reported $194.8 million in revenue for the quarter and $796.9 million for the full year, with an adjusted EBITDA of $270.5 million. Earnings per share were $0.09, beating estimates of $0.07. Management cited headwinds from the Rite Aid bankruptcy and lower integrated savings program volume, but expressed confidence in returning to growth beyond 2026 and expanding its role in the healthcare ecosystem.
Market reaction to the announcement was positive. Shares advanced steadily on Wednesday, reflecting investor enthusiasm for the expansion of GLP‑1 access and the growing self‑pay market. The move reinforces GoodRx’s competitive advantage as a facilitator of high‑cost drug access.
Wendy Barnes, GoodRx President and CEO, said, "Pharmaceutical innovation is moving quickly to meet the evolving needs of patients, and access has to keep pace. Wegovy HD is a strong example of how manufacturers are expanding options to support patients at different stages of treatment. GoodRx is proud to help translate that innovation into real‑world access, connecting patients to the FDA‑approved therapies and dosing they need with clear, predictable pricing." Novo Nordisk’s Ed Cinca added, "We're continuing to expand the Wegovy® portfolio with a simple goal: give patients the right option at the right time in their treatment. Wegovy® HD adds another FDA‑approved option to meet patients' clinical needs. Working with GoodRx helps make these medicines easier to access for the people who need them."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.